agree, as per the PK headline:
- effective target cells engaged (intracellular miracle in itself)
- long cellular engagement duration (relatively)
- safe (min off targets reported)
PYC pipeline image has been refreshed on their website to list OPA1 as a co-lead, anticipate refining of the shared delivery backbone to show even greater effectiveness/efficiency data.
Rinse and repeat hopefully for Glaucoma and other IRD.
And then there’s CNS/Kidney to come.
Ann: PK STUDY RESULTS MOVE RP11 CLOSER TO FIRST IN HUMAN TRIALS, page-28
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.29 |
Change
0.045(3.63%) |
Mkt cap ! $749.4M | |||
| Open | High | Low | Value | Volume |
| $1.25 | $1.29 | $1.25 | $337.0K | 265.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 300 | $1.23 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.29 | 58344 | 1 |
View Market Depth
| Last trade - 16.10pm 25/06/2025 (20 minute delay) ? |
| PYC (ASX) Chart |